- SKYLINE Study in Dravet Syndrome Narrowly Missed its Primary Endpoint of Reduction in Convulsive Seizure Frequency and Showed Clinically Meaningful and Nominally Significant Effects in Multiple Key Secondary Efficacy Endpoints
- SKYWAY Study in Lennox-Gastaut Syndrome Missed its Primary Endpoint of Reduction in Major Motor Drop Seizures
- Soticlestat Showed a Consistent and Favorable Safety and Tolerability Profile in Both Studies
- Takeda Will Move Forward to Discuss the Totality of the Data with Regulatory Authorities
Takeda Announced Topline Data From SKYLINE And SKYWAY Phase 3 Studies Of Soticlestat (TAK-935) Plus Standard Of Care Versus Placebo Plus Standard Of Care For Refractory Dravet Syndrome, Both The Studies Missed Their Primary Endpoints
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.